

CHALLENGES AND OPPORTUNITIES OF CELL & GENE THERAPY IN THE NEW ERA

DATE: January 15th, 2025

LOCATION: SAN FRANCISCO MARRIOTT MARQUIS & LIVESTREAM

GenScript Biotech Global Forum- 2024 Highlights





2024 Event Page >>





Deep insight from keynote speakers

- David Liu, Ph.D., Professor and Investigator at Broad Institute, Harvard University, and HHMI
- Peter Marks, Ph.D., Director, Center for Biologics Evaluation and Research, FDA

And from leaders in over **20 academic, investment, and business sectors advancing cell and gene therapies.**

- Nina Shah, M.D., Haematology Research & Development, AstraZeneca
- **Ken Prentice,** VP, Head of Process and Product Development, Shape Therapeutics
- **Devyn Smith**, Ph.D. CEO, Arbor Biotech
- Adrian Bot, Ph.D. CSO and EVP R&D, Capstan Therapeutics







Leaders Charting the Future of the CGT Industry



Identifying
emerging trends &
commercialization
paths

CAR-T Leaders Driving Commercialization



What Lies Ahead for CGT Commercialization Amid Funding Frenzy



Forging new partnerships

1,000+
Registrants



Bringing Fresh Energy & Innovation









Inaugural session in Europe

Nov 2024, London UK GenScript Biotech Global Forum

Jan 2024, San Francisco U.S. GenScript Biotech Global Forum

May 2023, Beijing China

GenScript Cell and Gene Therapy Industry
Development and Cooperation Forum

Jan 2020, San
Francisco U.S.
GenScript Biotech
Global Forum

Jul 2020, Shanghai China

GenScript Cell and Gene Therapy Industry Development and Cooperation Forum Dec 2021, Nanjing China SynBio &Gene Cell Therapy Industrial Chain Forum November 2022, Virtual
GenScript Cell
and Gene
Therapy Industry
Development
and Cooperation

Forum

Stimulating
Collaboration
Globally for a
Thriving CGT
Industry

Speakers from Past GenScript Cell & Gene Therapy Forums



Miguel Forte, M.D., Ph.D.

President of the International Society for Cell & Gene Therapy (ISCT), ARM Board Member, and CEO of Kiji Therapeutics

David Liu, Ph.D.

Professor and Investigator at Broad Institute, Harvard University, and HHMI

Scott Gottlieb, M.D.

Former FDA Commissioner

Dan Kaufman, M.D.

Professor of Medicine, Director of Cell Therapy Program, UC San Diego Moores Cancer Center

Ying Huang, Ph.D.

CEO, Legend Biotech

John Dawson

CEO, Oxford Biomedica

Becky Wood

Head of Sidley's Food, Drug, and Medical Device Regulatory Practice, Former FDA Chief Counsel

James Wilson, M.D., Ph.D.

President & CEO of Gemma Biotherapeutics (GEMMABio); Founder and Advisor of Scout Bio, Passage Bio, iECURE; Executive Chair at Franklin Biolabs

Peter Marks

Director, Center for Biologics Evaluation & Research (CEBR), FDA

Linfa Wang, Professor

Member of the Australian Academy of Technology and Engineering; Program in Emerging Infectious Diseases, Duke NUS Medical School, Singapore

Usman Azam, M.D.

CEO, Tmunity Therapeutics

Frederic Revah, Ph.D.

CEO, Genethon

Ke Liu, M.D.

Associate Director for Cell and Gene Therapy, Oncology Center of Excellence & Chief of Oncology Branch, FDA

Bruce Levine, Ph.D.

Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine

Peter Emtage, Ph.D.

Global Head of Cell Therapy Research, Kite Pharma, a Gilead Company

Laurence Cooper, M.D.

CEO, Ziopharm Oncology

James Li

CEO and Co-founder, JW Therapeutics

Hai Huang

CEO, Fosun Kite

Jules Hoffmann, Ph.D.

Chair of Integrative Biology, University of Strasbourg Institute for Advanced Study (USIAS), 2011 Nobel Laureate in Physiology or Medicine

Phil Vanek, Ph.D.

GM of Cell and Gene Therapy Strategy and Business Development, GE Healthcare Life Sciences

Simone Fishburn, Ph.D.

VP and Editor in Chief, BioCentury

Brad Loncar

Founder & CEO, Loncar Investment

Zhigang Tian, Academic

Member of the Chinese Academy of Engineering, Member of the European Academy of Sciences, Dean of the School of Basic Medicine (USTC)



2025 GenScript BIOTECH GLOBAL FORUM



CHALLENGES AND OPPORTUNITIES OF CELL AND GENE THERAPY IN THE NEW ERA

12:30 - 1:30 PM

Registration

1:30 - 1:45 PM

Welcome and Introduction

1:45 - 2:15 PM

Featured Speech by **Tom Whitehead**

2:15 - 2:55 PM

Keynote Speech by Dr. Carl June

2:55 - 3:30 PM

Keynote Speech by Dr. Peter Marks

3:35 - 4:05 PM

Panel I: 2025 Cell and Gene Therapy Market Outlook

4:05 - 5:00 PM

Panel II: Conquering CGT's challenges in biomanufacturing and supply chain management

5:00 - 5:55 PM

Panel III: How new therapeutic and technology platforms are shaping the future of CGT

5:55 - 6:00 PM

Closing

6:00 - 7:30 PM

Reception

20+ Renowned Speakers

3 Expert Panel Discussions

550+ CGT-Field Attendees

2025 Featured and Keynote Speakers



Featured Speaker



Tom Whitehead

Co-founder, Emily Whitehead Foundation

Topic: In This Together: How Our Family's Journey with Emily Sparked a Revolution in Cancer Treatment

Keynote Speaker



Dr. Carl June

Richard W. Vague Professor in Immunotherapy Professor of Medicine

Topic: (to be provided)

Keynote Speaker



Dr. Peter Marks

Director, Center for Biologics Evaluation and Research US Food and Drug Administration

Topic: The 2025 regulatory landscape for Cell and Gene Therapy

2025 Panel Speakers



PANEL I

2025 Cell and Gene Therapy Market Out

This insightful discussion will explore emerging trends, market dynamics, and future opportunities within the rapidly evolving cell and gene therapy landscape.



Vincent Xiang
Founder & Managing
Partner
7G BioVentures



Alan BashPresident of CARVYKTI

Legend Biotech



Bin LiFounder and CIO
Lake Bleu Capital



Caroline Stout
Partner
EcoR1 Capital



Josh Resnick
Senior Managing
Director
RA Capital
Management, L.P.



Yan Zhu
Vice President,
Head of Global
Open Innovation
Mitsubishi
Tanabe Pharma
America, Inc.

2025 Panel Speakers



PANEL II

Conquering CGT's Challenges in Biomanufacturing and **Supply Chain Management**

The discussion will showcase the latest advancements such as automation, supply chain, and quality control testing throughout the CGT manufacturing workflow.



Matthew Pillar Chief Editor, Bioprocess Online, Life Science Connect



Hari Pujar Operating Partner, Flagship Pioneering COO, Tessera Therapeutics



Hing Wong Founder & Chief Executive Officer, HCW Biologics Inc.



Jason Bock CEO CTMC



Senior Advisor, Multiply Labs / Director, Advanced Biotherapy Center, Sheba Medical Center Multiply Labs / Sheba Medical Center



Michael Vreeland **US Site Head** ProBio



Rey Mali Chief Business Officer Accellix

2025 Panel Speakers



PANEL III

How New Therapeutic and Technology Platforms are Shaping the Future of CGT

This discussion will delve into how innovative CAR-T designs, advanced stem cell processes, and novel genetic engineering platforms are poised to shape the future of cell and gene therapy.



Lori Ellis

Head of Insights,
BioSpace



Daniel Shelly
Chief Business
Development Officer
POITREG SA



Guowei Fang *President, Research and Development*



CEO
Rampart Bioscience, Inc.



Madhusudan
Peshwa
CEO,
MKC
Biotherapeutics, Inc.



Massimiliano
Paganelli
CEO,
Morphocell Technologies



Reagan Jarvis
Co-founder, CEO
Anocca



2025 GENSCRIPT
BIOTECH GLOBAL FORUM

DATE: January 15th, 2025

LOCATION: SAN FRANCISCO MARRIOTT MARQUIS, CA & LIVESTREAM

